WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metabolic and Inflammatory Research

Executive Summary: WY-14643 (Pirinixic Acid) is a potent and selective agonist of PPARα, with an IC50 of 10.11 µM in human assays. It modulates lipid metabolism and inflammatory signaling, notably downregulating TNF-α-induced VCAM-1 in endothelial cells. In animal studies, oral administration (3 mg/kg/day, 2 weeks) significantly lowers plasma glucose and triglycerides, and improves insulin sensitivity without increasing body weight. Aliphatic α-substitution enhances its dual PPARα/γ agonism. These features position WY-14643 as a reference compound for metabolic and inflammatory disorder modeling (APExBIO A4305; Bao et al., 2025).

Biological Rationale

Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that regulate key aspects of lipid and glucose homeostasis. PPARα is predominantly expressed in the liver, heart, muscle, and kidney, where it orchestrates fatty acid oxidation and lipoprotein metabolism (Bao et al., 2025). Dysregulation of PPARα activity is implicated in metabolic syndromes, nonalcoholic fatty liver disease, and inflammatory conditions. Agonists such as WY-14643 provide experimental leverage to dissect PPARα function and its crosstalk with inflammatory mediators, including TNF-α and VCAM-1. Studies in pulmonary lymphoepithelioma-like carcinoma (pLELC) further demonstrate that PPARα activation modulates tumor microenvironments by controlling tissue factor (TF) expression in response to fatty acids like linoleic acid (Bao et al., 2025).

Mechanism of Action of WY-14643 (Pirinixic Acid)

WY-14643 binds to and activates PPARα, a ligand-inducible transcription factor. Upon agonist binding, PPARα forms a heterodimer with retinoid X receptor (RXR) and translocates to peroxisome proliferator response elements (PPREs) in DNA, modulating the transcription of genes involved in fatty acid oxidation, inflammation, and cellular proliferation. The human PPARα IC50 for WY-14643 is 10.11 µM (APExBIO). Aliphatic α-substitution on the WY-14643 scaffold yields balanced dual PPARα/γ agonists with activity in the low micromolar range. Notably, WY-14643 suppresses TNF-α-induced expression of VCAM-1 and monocyte adhesion in endothelial cells at 250 μM, reflecting anti-inflammatory efficacy. In hepatic tissue, it elevates TNFα mRNA via Kupffer cell activation, indirectly promoting hepatocyte mitogenesis. These mechanisms intersect with the regulation of metabolic flux and the inflammatory milieu in various disease models (Bao et al., 2025).

Evidence & Benchmarks

• WY-14643 exhibits a human PPARα IC50 of 10.11 µM, demonstrating high selectivity and potency (APExBIO).
• Aliphatic α-substitution enhances dual PPARα/γ agonism, yielding balanced activity in the low micromolar range (APExBIO).
• In endothelial cells, 250 μM WY-14643 pretreatment significantly downregulates TNF-α-induced VCAM-1 and reduces monocyte adhesion (Bao et al., 2025).
• Oral administration of 3 mg/kg/day WY-14643 for 2 weeks in high fat-fed rats lowers plasma glucose, triglycerides, leptin, muscle triglycerides, and long-chain acyl-CoAs, while reducing visceral fat and liver triglyceride content and enhancing insulin sensitivity, without increasing body weight (Bao et al., 2025).
• Activation of PPARα by WY-14643 upregulates tissue factor (TF) expression in the presence of linoleic acid, altering immune cell infiltration and tumor progression in pLELC models (Bao et al., 2025).

This article extends the findings in "WY-14643 (Pirinixic Acid): PPARα Agonist Redefining Metab..." by detailing quantitative benchmarks and emphasizing dual PPARα/γ activity at the molecular level. For workflow guidance, "WY-14643 (Pirinixic Acid): Reproducible Workflows for Cel..." offers bench-level protocols, while this article focuses on recent evidence and mechanistic clarity.

Applications, Limits & Misconceptions

WY-14643 (Pirinixic Acid) is widely used in metabolic disorder research, PPAR signaling pathway analysis, and studies of TNF-α mediated inflammation. Its selectivity allows for precise dissection of PPARα-driven gene expression and metabolic remodeling. The compound is suitable for:

• Investigating lipid metabolism regulation in vitro and in vivo
• Elucidating PPARα/γ crosstalk in metabolic and inflammatory signaling
• Modeling insulin sensitivity enhancement in preclinical rodent studies
• Analysis of tumor microenvironment modulation via TF and immune infiltration

However, several boundaries must be recognized:

Common Pitfalls or Misconceptions

• WY-14643 is not water-soluble; improper vehicle selection can result in precipitation and confounded results. Use DMSO (≥16.2 mg/mL) or ethanol (≥48.8 mg/mL with ultrasonic assistance).
• It is not approved for diagnostic or medical use; applications are strictly for scientific research (APExBIO).
• Results from rodent models may not directly translate to human metabolic disease due to interspecies differences in PPARα activity.
• Over-interpretation of dual PPARα/γ effects can occur; confirm with receptor-specific assays.
• Long-term solution stability is limited; store at -20°C and use solutions promptly to avoid degradation.

This article updates mechanistic and benchmark data compared to "WY-14643 (Pirinixic Acid): Advancing Metabolic Disorder R..." by integrating recent findings on immune modulation and TF regulation.

Workflow Integration & Parameters

WY-14643 (Pirinixic Acid, SKU A4305) from APExBIO is supplied as a solid compound for research use. For optimal experimental results:

• Dissolve in DMSO (≥16.2 mg/mL) or ethanol (≥48.8 mg/mL, ultrasonic-assisted); avoid aqueous solvents.
• Store at -20°C; minimize freeze-thaw cycles; use solutions within days for best reproducibility.
• For in vitro studies, typical concentrations range from 10–250 μM, validated for PPARα/γ activation and anti-inflammatory assays.
• For in vivo rodent models, oral dosing at 3 mg/kg/day for 2 weeks is effective for metabolic endpoints.

For integration into cell-based or animal workflows, reference the detailed protocols in "WY-14643 (Pirinixic Acid): Reproducible Workflows for Cel...", which complements this article's focus on molecular evidence and benchmarks.

Conclusion & Outlook

WY-14643 (Pirinixic Acid) is a validated, selective PPARα agonist and dual PPARα/γ modulator with robust utility in metabolic and inflammatory research. Its effects on lipid metabolism, insulin sensitivity, and immune cell infiltration are quantitatively benchmarked and reproducible across preclinical models. Future directions include the use of WY-14643 in advanced studies of tumor microenvironment and metabolic-inflammation crosstalk. For full product details and ordering, visit the APExBIO WY-14643 (Pirinixic Acid) page.